Association of CYP2B6, CYP3A5, and CYP2C19 Genetic Polymorphisms With Sibutramine Pharmacokinetics in Healthy Korean Subjects (Q29308187)

9 April 2017

1 reference

1 reference

K A Kim

1

1 reference

9 April 2017

W K Song

series ordinal

2

1 reference

9 April 2017

J Y Park

series ordinal

3

1 reference

9 April 2017

language of work or name

English

0 references

publication date

19 August 2009

1 reference

Clinical Pharmacology & Therapeutics

9 April 2017

published in

1 reference

9 April 2017

volume

86

1 reference

9 April 2017

issue

5

1 reference

9 April 2017

page(s)

511-518

1 reference

Sibutramine: a serotonin-norepinephrine reuptake-inhibitor for the treatment of obesity

9 April 2017

cites work

1 reference

https://api.crossref.org/works/10.1038/CLPT.2009.145

Inhibition of cytochrome P450 (CYP450) isoforms by isoniazid: potent inhibition of CYP2C19 and CYP3A

21 April 2017

1 reference

https://api.crossref.org/works/10.1038/CLPT.2009.145

Clinical significance of the cytochrome P450 2C19 genetic polymorphism

21 April 2017

1 reference

https://api.crossref.org/works/10.1038/CLPT.2009.145

An assessment of the safety and efficacy of sibutramine, an anti-obesity drug with a novel mechanism of action

21 April 2017

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.145

Sibutramine pharmacokinetics in young and elderly healthy subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.145

The contribution of metabolites to the rapid and potent down-regulation of rat cortical beta-adrenoceptors by the putative antidepressant sibutramine hydrochloride

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.145

Cytochrome P450 2B6 catalyzes the formation of pharmacologically active sibutramine (N-{1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutyl}-N,N-dimethylamine) metabolites in human liver microsomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.145

Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.145

Effect of CYP3A5*3 genotype on the pharmacokinetics and pharmacodynamics of amlodipine in healthy Korean subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.145

Effect of CYP3A5*3 genotype on the pharmacokinetics and pharmacodynamics of alprazolam in healthy subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.145

The effect of CYP2C19 polymorphism on the pharmacokinetics and pharmacodynamics of clopidogrel: a possible mechanism for clopidogrel resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.145

Effect of CYP3A5*3 genotype on the pharmacokinetics and antiplatelet effect of clopidogrel in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.145

Pharmacogenetics of cytochrome P450 and its applications in drug therapy: the past, present and future

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.145

Clinical implications of pharmacogenetics of cytochrome P450 drug metabolizing enzymes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.145

Sibutramine-induced acute myocardial infarction in a young lady

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.145

Sibutramine-associated QT interval prolongation and cardiac arrest

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.145

QT interval prolongation associated with sibutramine treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.145

Genetic polymorphism of cytochrome P450s, CYP2C19, and CYP2C9 in a Japanese population

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.145

Enantioselective disposition of lansoprazole in extensive and poor metabolizers of CYP2C19.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.145

Bupropion and 4-OH-bupropion pharmacokinetics in relation to genetic polymorphisms in CYP2B6

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.145

Polymorphisms of drug-metabolizing enzymes (GST, CYP2B6 and CYP3A) affect the pharmacokinetics of thiotepa and tepa

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.145

Effect of polymorphic CYP3A5 genotype on the single-dose simvastatin pharmacokinetics in healthy subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.145

Effect of cytochrome P450 3A5*3 genotype on the stereoselective pharmacokinetics of amlodipine in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.145

CYP2C19‐ and CYP3A4‐Dependent Omeprazole Metabolism in West Mexicans

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.145

Identification of cytochrome P450 isoforms involved in the metabolism of loperamide in human liver microsomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.145

Sibutramine-associated adverse effects: a practical guide for its safe use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.145

FDA is incapable of protecting US "against another Vioxx".

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.145

Efficacy and safety of sibutramine in 2225 subjects with cardiovascular risk factors: short-term, open-label, observational study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.145

Effect of sibutramine HCl on cardiac hERG K+ channel

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.145

Relative bioavailability and pharmacokinetics of a new sibutramine formulation in healthy male subjects: a randomized, open-label, two-period, comparative crossover study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.145

Pyrosequencing-based screening for genetic polymorphisms in cytochrome P450 2B6 of potential clinical relevance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.145

Sibutramine and its cardiovascular profile

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.145

7 January 2021

Allele and genotype frequencies of CYP2B6 and CYP3A5 in the Japanese population

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.145

7 January 2021

Sibutramine: current status as an anti-obesity drug and its future perspectives

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.145

7 January 2021

Frequency distribution of dapsone N-hydroxylase, a putative probe for P4503A4 activity, in a white population

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.145

7 January 2021

Meta-analysis of phenotype and genotype of NAT2 deficiency in Chinese populations

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.145

7 January 2021

Identifiers

DOI

10.1038/CLPT.2009.145

1 reference